Impact of Adherence to Antihypertensive Agents on Clinical Outcomes and Hospitalization Costs
The DOI matches its Crossref record; 39 of the 41 references it cites were found in a registry or an index.
Abstract
Background Cardiovascular diseases (CVD) represent a heavy economic burden on individuals, health services, and society. Low adherence to antihypertensive (AH) agents is acknowledged as a major contributor to the lack of blood pressure control, and may have a significant impact on clinical outcomes and healthcare costs. Objectives To evaluate the impact of low adherence to AH agents on cardiovascular outcomes and hospitalization costs. Methods A cohort of 59,647 patients with essential hypertension was reconstructed from the Régie de l'assurance maladie du Québec and Med-Echo databases. Subjects included were between 45 and 85 years of age, without any evidence for symptomatic CVD, newly treated with AH agents between 1999 and 2002 and followed-up for a 3-year period. Adherence to AH agents was categorized as >or=80% or Results Patients with low adherence were more likely to have coronary disease (OR, 1.07; 95% confidence interval [CI], 1.00-1.13), cerebrovascular disease (OR, 1.13; 95% CI, 1.03-1.25), and chronic heart failure (OR, 1.42; 95% CI, 1.27-1.58) within the 3-year follow-up period. Among hospitalized patients, low adherence to AH therapy was associated with increased costs by approximately $3574 (95% CI, $2897-$4249) per person within a 3-year period. Conclusions Low adherence to AH agents is correlated with a higher risk of vascular events, hospitalization, and greater healthcare costs. An increased level of adherence to AH agents should provide a better health st…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Reinforcing measures aimed at improving adherence to treatment is cost effective. 31,32”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [32]
In the citing paper
“Reinforcing measures aimed at improving adherence to treatment is cost effective.31,32”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [32]
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2101 · Cited by 4,177
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost
Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005) · Medical Care · doi:10.1097/01.mlr.0000163641.86870.af · Cited by 1,729
A meta-analysis of the association between adherence to drug therapy and mortality
Simpson, S. H., Eurich, D. T., Majumdar, S. R., Padwal, R. S., Tsuyuki, R. T., Varney, J., & Johnson, J. A. (2006) · BMJ · doi:10.1136/bmj.38875.675486.55 · Cited by 1,353 · cited 1×
“The observed relation between good adherence to placebo and mortality supports the importance of the healthy adherer effect, where adherence to medication may be a marker of overall healthy behavior.(37) However, based on the differential class effects of drug adherence on long-term survival, it FIGURE 1.”
BackgroundHypertension Treatment and Control in Five European Countries, Canada, and the United States
Wolf-Maier, K., Cooper, R. S., Kramer, H., Banegas, J. R., Giampaoli, S., Joffres, M. R., Poulter, N., Primatesta, P., Stegmayr, B., & Thamm, M. (2004) · Hypertension · doi:10.1161/01.hyp.0000103630.72812.10 · Cited by 1,083
Methods for evaluation of medication adherence and persistence using automated databases
Andrade, S. E., Kahler, K. H., Frech, F., & Chan, K. A. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1230 · Cited by 1,079
A chronic disease score from automated pharmacy data
Von Korff, M., Wagner, E. H., & Saunders, K. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90016-g · Cited by 961
Hess, L. M., Raebel, M. A., Conner, D. A., & Malone, D. C. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h018 · Cited by 756
Much ado about two: reconsidering retransformation and the two-part model in health econometrics
Mullahy, J. (1998) · Journal of Health Economics · doi:10.1016/s0167-6296(98)00030-7 · Cited by 690
METHODS FOR ANALYZING HEALTH CARE UTILIZATION AND COSTS
Diehr, P., Yanez, D., Ash, A., Hornbrook, M., & Lin, D. Y. (1999) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.20.1.125 · Cited by 663
Neoptolemos, J., Kemppainen, E., Mayer, J., Fitzpatrick, J., Raraty, M., Slavin, J., Beger, H.-G., Hietaranta, A., & Puolakkainen, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02327-8 · Cited by 623
Collins, R., & MacMahon, S. (1994) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a072892 · Cited by 587
Ho, P. M., Magid, D. J., Shetterly, S. M., Olson, K. L., Maddox, T. M., Peterson, P. N., Masoudi, F. A., & Rumsfeld, J. S. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.12.011 · Cited by 587
Tamblyn, R., Lavoie, G., Petrella, L., & Monette, J. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00234-h · Cited by 577 · cited 1×
“The pharmaceutical database has been evaluated and its validity confirmed.(16) Moreover, validity studies have been done for several medical services claims contained in the Quebec administrative databases.”
MethodChoo, P. W., Rand, C. S., Inui, T. S., Lee, M.-L. T., Cain, E., Cordeiro-Breault, M., Canning, C., & Platt, R. (1999) · Medical Care · doi:10.1097/00005650-199909000-00002 · Cited by 546
Haukoos, J. S., & Lewis, R. J. (2005) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2005.tb01958.x · Cited by 540
Cost-of-Illness Studies: A Major Headache?
Drummond, M. (1992) · PharmacoEconomics · doi:10.2165/00019053-199202010-00001 · Cited by 489
Confounding by Indication: An Example of Variation in the Use of Epidemiologic Terminology
Salas, M., Hotman, A., & Stricker, B. H. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009758 · Cited by 471
Validation of diagnostic codes within medical services claims
Wilchesky, M., Tamblyn, R. M., & Huang, A. (2004) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(03)00246-4 · Cited by 439
Schroeder, K., Fahey, T., & Ebrahim, S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.7.722 · Cited by 416
Bramley, T. J., Nightengale, B. S., Frech-Tamas, F., & Gerbino, P. P. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.3.239 · Cited by 380 · cited 1×
“The MPR was dichotomized by setting the MPR threshold at 80%.(23,24)”
MethodWang, P. S., Bohn, R. L., Knight, E., Glynn, R. J., Mogun, H., & Avorn, J. (2002) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2002.00406.x · Cited by 373
Cost-of-Illness Studies: A Review of Current Methods
Akobundu, E., Ju, J., Blatt, L., & Mullins, C. D. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624090-00005 · Cited by 279
Methods for Improving Regression Analysis for Skewed Continuous or Counted Responses
Afifi, A. A., Kotlerman, J. B., Ettner, S. L., & Cowan, M. (2007) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.28.082206.094100 · Cited by 263
Prevalence and incidence of hypertension from 1995 to 2005: a population-based study
Tu, K., Chen, Z., Lipscombe, L. L., & Taskforce, F. T. C. H. E. P. O. R. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071283 · Cited by 254
Results of the Ontario Survey on the Prevalence and Control of Hypertension
Leenen, F. H. H., Dumais, J., McInnis, N. H., Turton, P., Stratychuk, L., Nemeth, K., Moy Lum-Kwong, M., & Fodor, G. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071340 · Cited by 248
Rizzo, J. A., & Robert Simons, W. (1997) · Clinical Therapeutics · doi:10.1016/s0149-2918(97)80018-5 · Cited by 174
Tamblyn, R. M., Reid, T., Mayo, N., McLeod, P., & Churchill-Smith, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00136-5 · Cited by 172
Kettani, F.-Z., Dragomir, A., Côté, R., Roy, L., Bérard, A., Blais, L., Lalonde, L., Moreau, P., & Perreault, S. (2009) · Stroke · doi:10.1161/strokeaha.108.522193 · Cited by 155
Self-citationDiscontinuation of statin therapy following an acute myocardial infarction: a population-based study
Daskalopoulou, S. S., Delaney, J. A. C., Filion, K. B., Brophy, J. M., Mayo, N. E., & Suissa, S. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn346 · Cited by 133
Nelson, M. R., Reid, C. M., Ryan, P., Willson, K., & Yelland, L. (2006) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00662.x · Cited by 108
Persistence with Treatment in Newly Treated Middle-Aged Patients with Essential Hypertension
Perreault, S. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e548 · Cited by 91
Self-citationAdherence level of antihypertensive agents in coronary artery disease
Perreault, S., Dragomir, A., Roy, L., White, M., Blais, L., Lalonde, L., & Bérard, A. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03547.x · Cited by 72
Self-citationBetter adherence to antihypertensive agents and risk reduction of chronic heart failure
Perreault, S., Dragomir, A., White, M., Lalonde, L., Blais, L., & Bérard, A. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02084.x · Cited by 70
Self-citationHypertension management in Canada: good news, but important challenges remain
Mohan, S., & Campbell, N. R. C. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080296 · Cited by 15
2013 Canadian Hypertension Education Program Recommendations
Vinall, P., & Oparil, S. (2013) · MD Conference Express · doi:10.1177/155989771302003 · Cited by 13
Cited by
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Economic impact of medication non-adherence by disease groups: a systematic review
Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-016982 · Cited by 900
Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences
Chowdhury, R., Khan, H., Heydon, E., Shroufi, A., Fahimi, S., Moore, C., Stricker, B., Mendis, S., Hofman, A., Mant, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht295 · Cited by 931
Self-report measures of medication adherence behavior: recommendations on optimal use
Stirratt, M. J., Dunbar-Jacob, J., Crane, H. M., Simoni, J. M., Czajkowski, S., Hilliard, M. E., Aikens, J. E., Hunter, C. M., Velligan, D. I., Huntley, K., et al. (2015) · Translational Behavioral Medicine · doi:10.1007/s13142-015-0315-2 · Cited by 824
Metadata
- Authors
- Dragomir, A., Côté, R., Roy, L., Blais, L., Lalonde, L., Bérard, A., & Perreault, S.
- Affiliations
- Université de Montréal (CA)
- McGill University (CA)
- Corresponding author
- Dragomir, Alice
- Blais, Lucie
- Lalonde, Lyne
- Bérard, Anick
- Perreault, Sylvie
- Venue
- Medical Care
- Published
- 2010-05
- Volume
- 48
- Issue
- 5
- Pages
- 418-425
- ISSN
- 0025-7079 (ISSN-L)
- OpenAlex
- W1966704625
- Cited by
- 221
- References
- 41
- Citations by year
- 2026: 9 · 2025: 3 · 2024: 8 · 2023: 9 · 2022: 19 · 2021: 6 · 2020: 14 · 2019: 16 · 2018: 13 · 2017: 20 · 2016: 13 · 2015: 14 · 2014: 20 · 2013: 21 · 2012: 20
- FWCI
- 16.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Medical Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- antihypertensive drugs, medication adherence, essential hypertension, cardiovascular disease, hospital costs, coronary disease, cerebrovascular disease, chronic heart failure, health care costs, blood pressure control
- MeSH terms
- Assessment of Medication Adherence, Age Factors, Aged, Aged, 80 and over, Antihypertensive Agents, Cardiovascular Diseases, Cerebrovascular Disorders, Coronary Artery Disease, Drug Therapy, Combination, Female, Heart Failure, Hospitalization, Humans, Hypertension, Insurance Claim Review, Male, Middle Aged, Sex Factors, Cohort Studies, Treatment Outcome, Drug Monitoring, Hospital Charges, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.